NeoGenomics - NEO Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NEO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NEO, but not buy additional shares or sell existing shares.
View NEO analyst ratings or view top-rated stocks.

11 analysts have issued 12 month price targets for NeoGenomics' stock. Their NEO share price forecasts range from $16.00 to $30.00. On average, they predict the company's stock price to reach $20.08 in the next year. This suggests a possible upside of 119.4% from the stock's current price.
View analysts price targets for NEO or view top-rated stocks among Wall Street analysts.

NeoGenomics' stock was trading at $34.12 at the start of the year. Since then, NEO shares have decreased by 73.2% and is now trading at $9.15.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NEO earnings forecast.

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Tuesday, August, 9th. The medical research company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.06. The medical research company had revenue of $125 million for the quarter, compared to analyst estimates of $123.26 million. NeoGenomics had a negative net margin of 30.00% and a negative trailing twelve-month return on equity of 8.53%. The company's revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) EPS.

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Moody National Bank Trust Division (0.01%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends.

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NEO stock can currently be purchased for approximately $9.15.

NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.15 billion and generates $484.33 million in revenue each year. The medical research company earns $-8,350,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

The company employs 2,000 workers across the globe.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.